Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 266

Sort by

Sort Order Select

Journal Articles

Odyssey: A first-in-human study of the aldehyde dehydrogenase (ALDH) inhibitor abd-3001 in patients with refractory/relapsed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS)

Mael Heiblig, Lina Benajiba, Julien Colle, Sandrine Loron, Juliette Soret, Rafael Daltro De Oliveira, Geoffroy Venton, Marie-Virginie Larcher, Laure Farnault, Mühübe Yazir, Mileidys Perez, Ismail Ceylan, Guillaume Martin, Annick Pelletier, Jean-Jacques Kiladjian, Régis Costello

Blood (2025) 146 (Supplement 1): 3421.

https://doi.org/10.1182/blood-2025-3421

Published: 2025

Journal Articles

Transfusion independence with momelotinib regardless of baseline erythropoietin levels in the Phase 3 SIMPLIFY-1 trial

Stephen Oh, Juan Carlos Hernandez Boluda, Jean-Jacques Kiladjian, Viviane Dubruille, Christian Recher, Alexandre Lockhart, Chandan Kumar, Hanny Musa, Jasmine Sahni, Dwaipayan Patnaik, Claire Harrison

Blood (2025) 146 (Supplement 1): 2025.

https://doi.org/10.1182/blood-2025-2025

Published: 2025

Journal Articles

Impact of new or worsening anemia and thrombocytopenia on clinical outcomes in JAK inhibitor–naive myelofibrosis patients treated with ruxolitinib

Vikas Gupta, Francesca Palandri, Jean-Jacques Kiladjian, Bethan Psaila, Bella Vo, Jessica Lim, Fulya Sen Nikitas, Shiyuan Zhang, Tom (sizhu) Liu, Catherine Ellis, Jasmine Sahni, Dwaipayan Patnaik, Stephen Oh, Ruben Mesa

Blood (2025) 146 (Supplement 1): 3809.

https://doi.org/10.1182/blood-2025-3809

Published: 2025

Journal Articles

The activin receptor-like kinase-2 inhibitor zilurgisertib (INCB000928) as monotherapy or with ruxolitinib in patients with anemia due to myelofibrosis: Phase 1/2 study final results

Blood (2025) 146 (Supplement 1): 3795.

https://doi.org/10.1182/blood-2025-3795

Published: 2025

Journal Articles

Efficacy and safety of luspatercept (LUSPA) versus placebo (PBO) in patients (pts) with myelofibrosis (MF) on Janus kinase 2 inhibitor (JAKi) therapy who require red blood cell transfusions (RBCT): primary analysis of the Phase 3 randomized INDEPENDENCE trial

Blood (2025) 146 (Supplement 1): 907.

https://doi.org/10.1182/blood-2025-907

Published: 2025

Journal Articles

Durable efficacy and long-term safety with pelabresib plus ruxolitinib in JAK Inhibitor–Naive myelofibrosis: 96-week Results from the Phase III MANIFEST-2 study

Blood (2025) 146 (Supplement 1): 910.

https://doi.org/10.1182/blood-2025-910

Published: 2025

Journal Articles

Nuvisertib, an oral investigational selective PIM1 kinase inhibitor, showed clinical responses strongly correlating with cytokine modulation in patients with relapsed/refractory myelofibrosis in the ongoing global phase I/II study

Blood (2025) 146 (Supplement 1): 2018.

https://doi.org/10.1182/blood-2025-2018

Published: 2025

Journal Articles

Correlation between interleukin (IL)-8 and tumor necrosis factor (TNF)-alpha levels and overall survival in patients (pts) with myelofibrosis (MF) relapsed or refractory (R/R) to a Janus-associated kinase inhibitor (JAKi) treated with imetelstat (IME) in the imbark trial

John Mascarenhas, Claire Harrison, Alessandro Lucchesi, Angela Fleischman, Rami Komrokji, Alessandro Maria Vannucchi, Jean-Jacques Kiladjian, Yiqun Yang, Libo Sun, Ying Wan, Michelle Mudge-Riley, Tymara Berry, Faye Feller, Fei Huang, Prithviraj Bose

Blood (2025) 146 (Supplement 1): 5585.

https://doi.org/10.1182/blood-2025-5585

Published: 2025

Journal Articles

Retromomelo: Real-world use of momelotinib – the french experience from the FIM group

Mathilde Chanut, Imane Belhadi, Emmanuel Raffoux, Juliette Soret, Geoffroy Venton, Vincent Alcazer, Lenaig Le Clech, Jean-Christophe Ianotto, Mathieu Meunier, Paul Denous Chataigner, Mathilde Hunault, Ugo Thévenet, Elsa Lestang, Antoine Bonnet, Rafael Daltro De Oliveira, Ahmad Aljijakli, Florence Sabirou, Lina Benajiba, Jean-Jacques Kiladjian

Blood (2025) 146 (Supplement 1): 7316.

https://doi.org/10.1182/blood-2025-7316

Published: 2025

Journal Articles

Ropeginterferon alfa-2b in essential thrombocythemia of all risk levels ineligible for standard cytoreduction: 12-month primary endpoint analysis from the ROP-ET phase 3 study

Blood (2025) 146 (Supplement 1): 485.

https://doi.org/10.1182/blood-2025-485

Published: 2025

Journal Articles

Preliminary data from the Phase I/II study of nuvisertib, an oral investigational selective PIM1 inhibitor, in combination with momelotinib showed clinical responses in patients with relapsed/refractory myelofibrosis

Blood (2025) 146 (Supplement 1): 482.

https://doi.org/10.1182/blood-2025-482

Published: 2025

Journal Articles

Safety and efficacy of INCA033989, a novel first in class mutant calreticulin-specific monoclonal antibody, in patients with essential thrombocythemia

Blood (2025) 146 (Supplement 1): 1024.

https://doi.org/10.1182/blood-2025-1024

Published: 2025

Journal Articles

Discovery and preclinical characterization of orally bioavailable JAK2V617F mutant selective JH2 inhibitors with disease modification potential in myeloproliferative neoplasms

Blood (2025) 146 (Supplement 1): 70.

https://doi.org/10.1182/blood-2025-70

Published: 2025

Journal Articles

Role of allo-HCT in “nonclassical” MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT

Nicola Polverelli, Juan Carlos Hernández-Boluda, Francesco Onida, Carmelo Gurnari, Kavita Raj, Tomasz Czerw, Michelle Kenyon, Marie Robin, Katja Sockel, Annalisa Ruggeri, Isabel Sánchez-Ortega, Daniel A. Arber, Luca Arcaini, Fernando Barroso Duarte, Giorgia Battipaglia, Yves Chalandon, Fabio Ciceri, Nicholas C. P. Cross, Joanna Drozd-Sokolowska, Vaneuza Funke, Nico Gagelmann, Naseema Gangat, Jason Gotlib, Paola Guglielmelli, Claire Harrison, Gabriela Hobbs, Tania Jain, Joseph D. Khoury, Jean Jacques Kiladjian, Nicolaus Kröger, Luca Malcovati, Massimo Martino, Ruben Mesa, Attilio Orazi, Eric Padron, Francesca Palandri, Francesco Passamonti, Mrinal M. Patnaik, Naveen Pemmaraju, Deepti H. Radia, Andreas Reiter, Domenico Russo, Christof Scheid, Ayalew Tefferi, Alessandro M. Vannucchi, Daniel H. Wiseman, Ibrahim Yakoub-Agha, Donal P. McLornan

Blood (2025) 145 (22): 2561–2573.

https://doi.org/10.1182/blood.2024028000

Published: 2025

Includes: Supplemental data

Journal Articles

Current myeloproliferative neoplasm scoring systems for clinical practice

Hélène Pasquer, Jean-Jacques Kiladjian, Lina Benajiba

Blood (2025) 145 (3): 257–276.

https://doi.org/10.1182/blood.2024025459

Published: 2025

Journal Articles

JAK Inhibition Results in Aggressive Cutaneous Squamous Cell Carcinoma through MAPK Pathway Activation and Shapes the Tumor Immune Microenvironment to Create Novel Therapeutic Opportunities

Blood (2024) 144 (Supplement 1): 4513.

https://doi.org/10.1182/blood-2024-205839

Published: 2024

Journal Articles

A Phase 1/2 Study of Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, in Combination with JAK Inhibitors Ruxolitinib or Momelotinib in Patients with Myelofibrosis

Blood (2024) 144 (Supplement 1): 6629.

https://doi.org/10.1182/blood-2024-200268

Published: 2024

Journal Articles

New Criteria for Evaluating Outcomes of Myelofibrosis Therapy

Monia Marchetti, Alessandro Maria Vannucchi, John O. Mascarenhas, Alberto Alvarez-Larran, Prithviraj Bose, Robert Peter Gale, Claire Harrison, Rüdiger Hehlmann, Jean-Jacques Kiladjian, Steffen Koschmieder, Ruben Mesa, Francesco Passamonti, Alessandro Rambaldi, Ayalew Tefferi, Tiziano Barbui

Blood (2024) 144 (Supplement 1): 7898.

https://doi.org/10.1182/blood-2024-198646

Published: 2024

Journal Articles

Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed or Refractory to Janus Kinase Inhibitor in IMpactMF, a Randomized, Open-Label, Phase 3 Trial

John O. Mascarenhas, Claire Harrison, Prithviraj Bose, Jean-Jacques Kiladjian, Alessandro Lucchesi, Alessandro Maria Vannucchi, Tymara Berry, Jennifer Riggs, Lixian Peng, Fei Huang, Ying Wan, Vivian Rodolf, Judy Ho, Shyamala Navada, Rami S. Komrokji

Blood (2024) 144 (Supplement 1): 1808.1.

https://doi.org/10.1182/blood-2024-199235

Published: 2024

Journal Articles

Results from the Randomized, Multicenter, Global Phase 3 BOREAS Study: Navtemadlin Versus Best Available Therapy in JAK Inhibitor Relapsed / Refractory Myelofibrosis

John O. Mascarenhas, Viola Maria Popov, Sanjay Mohan, Zübeyde Nur Özkurt, Jean-Jacques Kiladjian, Haifa Kathrin Al-Ali, Andrew Perkins, Zhuying Huang, Hope Qamoos, Jesse McGreivy, Wayne Rothbaum, Srdan Verstovsek, Maciej Kaźmierczak

Blood (2024) 144 (Supplement 1): 1000.

https://doi.org/10.1182/blood-2024-201642

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Odyssey: A first-in-human study of the aldehyde dehydrogenase (ALDH) inhibitor abd-3001 in patients with refractory/relapsed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS)

Transfusion independence with momelotinib regardless of baseline erythropoietin levels in the Phase 3 SIMPLIFY-1 trial

Impact of new or worsening anemia and thrombocytopenia on clinical outcomes in JAK inhibitor–naive myelofibrosis patients treated with ruxolitinib

The activin receptor-like kinase-2 inhibitor zilurgisertib (INCB000928) as monotherapy or with ruxolitinib in patients with anemia due to myelofibrosis: Phase 1/2 study final results

Efficacy and safety of luspatercept (LUSPA) versus placebo (PBO) in patients (pts) with myelofibrosis (MF) on Janus kinase 2 inhibitor (JAKi) therapy who require red blood cell transfusions (RBCT): primary analysis of the Phase 3 randomized INDEPENDENCE trial

Durable efficacy and long-term safety with pelabresib plus ruxolitinib in JAK Inhibitor–Naive myelofibrosis: 96-week Results from the Phase III MANIFEST-2 study

Nuvisertib, an oral investigational selective PIM1 kinase inhibitor, showed clinical responses strongly correlating with cytokine modulation in patients with relapsed/refractory myelofibrosis in the ongoing global phase I/II study

Correlation between interleukin (IL)-8 and tumor necrosis factor (TNF)-alpha levels and overall survival in patients (pts) with myelofibrosis (MF) relapsed or refractory (R/R) to a Janus-associated kinase inhibitor (JAKi) treated with imetelstat (IME) in the imbark trial

Retromomelo: Real-world use of momelotinib – the french experience from the FIM group

Ropeginterferon alfa-2b in essential thrombocythemia of all risk levels ineligible for standard cytoreduction: 12-month primary endpoint analysis from the ROP-ET phase 3 study

Preliminary data from the Phase I/II study of nuvisertib, an oral investigational selective PIM1 inhibitor, in combination with momelotinib showed clinical responses in patients with relapsed/refractory myelofibrosis

Safety and efficacy of INCA033989, a novel first in class mutant calreticulin-specific monoclonal antibody, in patients with essential thrombocythemia

Discovery and preclinical characterization of orally bioavailable JAK2V617F mutant selective JH2 inhibitors with disease modification potential in myeloproliferative neoplasms

Role of allo-HCT in “nonclassical” MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT

Current myeloproliferative neoplasm scoring systems for clinical practice

JAK Inhibition Results in Aggressive Cutaneous Squamous Cell Carcinoma through MAPK Pathway Activation and Shapes the Tumor Immune Microenvironment to Create Novel Therapeutic Opportunities

A Phase 1/2 Study of Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, in Combination with JAK Inhibitors Ruxolitinib or Momelotinib in Patients with Myelofibrosis

New Criteria for Evaluating Outcomes of Myelofibrosis Therapy

Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed or Refractory to Janus Kinase Inhibitor in IMpactMF, a Randomized, Open-Label, Phase 3 Trial

Results from the Randomized, Multicenter, Global Phase 3 BOREAS Study: Navtemadlin Versus Best Available Therapy in JAK Inhibitor Relapsed / Refractory Myelofibrosis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only